Elanco Animal Health (ELAN) Cash from Financing Activities (2017 - 2026)

Elanco Animal Health has disclosed Cash from Financing Activities across 10 years of filings, most recently posting -$65.0 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$65.0 million, down 225.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$392.0 million (up 72.26% YoY), and the FY2025 annual result was -$275.0 million, up 81.57% from the prior year.
• Cash from Financing Activities came in at -$65.0 million for Q1 2026 at Elanco Animal Health, down from -$18.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $174.0 million in Q1 2023 to a low of -$1.3 billion in Q3 2024.
• The 5-year median for Cash from Financing Activities is -$93.0 million (2024), against an average of -$144.9 million.
• Across the five-year window, Cash from Financing Activities slumped 10100.0% in 2022 and soared 292.59% in 2025, its largest moves.
• Elanco Animal Health's Cash from Financing Activities stood at -$84.0 million in 2022, then sank by 65.48% to -$139.0 million in 2023, then surged by 76.98% to -$32.0 million in 2024, then surged by 43.75% to -$18.0 million in 2025, then tumbled by 261.11% to -$65.0 million in 2026.
• The last three Cash from Financing Activities figures came in at -$65.0 million (Q1 2026), -$18.0 million (Q4 2025), and -$153.0 million (Q3 2025), per Business Quant data.